Previous 10 | Next 10 |
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Paul Tebbe...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be p...
DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be p...
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a con...
DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the launch of its wholly-owne...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces the addition of Mark Pryor, former ...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization providing state-of-the-art large molecule contract development...
DURHAM, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , an integrated contract development and manufacturing organization (CDMO), received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation st...
DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a ...